Profile
| Role | Insider |
|---|---|
| Notability | 20/100 |
Board memberships
- enGene Holdings Inc.
Updated Jul 16, 2026
Astley-Sparke Philip has filed 2 SEC Form 4 filings across 2 companies in the last 90 days — selling. Lifetime open-market sales: $90K.
| Role | Insider |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-20 | REPL | Replimune Group, Inc. | S — Open-market sale | 17.7K | $5.08 | $90K |
| 2026-04-08 | REPL | Replimune Group, Inc. | A — Grant or award | 50.0K | $0.00 | |
| 2026-02-20 | REPL | Replimune Group, Inc. | G — Bona-fide gift | 25.0K | $0.00 |
Astley-Sparke Philip is a corporate insider — currently tracked as Insider of enGene Therapeutics Inc. (ENGN). InsiderAlpha tracks every SEC Form 4 filing in real time.
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Recorded transactions: 0 open-market purchases () and 1 open-market sales ($90K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Astley-Sparke Philip profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.